Clinical Trial Details

A single arm phase II study of Adjuvant Endocrine therapy, subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT) (DF/HCC 20-347)

This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer.

The study drugs involved in this study are:

  • A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO)
  • Hormonal (endocrine) Treatment

Learn More

Principal Investigator(s)

Steve Lo, MD


Mary Miller, LPN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.